EUCTR2020-002293-28-SE进行中（未招募）1 期
Resolving inflammatory storm in COVID-19 patients by Omega-3 polyunsaturated fatty acids.- A single-blind, randomized, placebo-controlled feasibility study
Karolinska University Hospital0 个研究点目标入组 40 人开始时间: 2020年5月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of signed informed consent prior to any study specific procedures.
- •2. Female and male patients =18 years of age.
- •3.COVID-19 positive or typical CT image of COVID-19 infection.
- •4. Clinical status requiring hospitalization.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. According to Omegaven® contraindications (serious bleeding disorders, acute life-threatening condition, including acute shock, acute myocardial infarction, acute stroke, acute emboli, and coma).
- •2. Known hypersensitivity to Omegaven or any of the ingredients.
- •3. Participation in any clinical research study evaluating an investigational medicinal product (IMP) within 3 months prior to screening.
- •4. Pregnancy and breastfeeding.
研究者
相似试验
已完成
不适用
Melatonin in COVID-19IRCT20200922048804N1Tehran University of Medical Sciences20
招募中
2 期
Treatment of COVID-19-induced cytokine storm by hemoperfusioIRCT20200317046797N5Tabriz University of Medical Sciences10
进行中（未招募）
1 期
Treatment of non-severe confirmed cases of coronavirus and treatment of their contacts as preventioSARS-CoV-2 Respiratory Viral InfectionMedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10070255Term: Coronavirus test positiveSystem Organ Class: 10022891 - InvestigationsEUCTR2020-001031-27-ESFUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA3,040
已完成
3 期
COVID-19: Reducing Symptoms and Hospitalization rates by use of Azelastine Nasal spray in patients suffering from COVID-19 in Early stagesTreatment of COVID-19 patientsDRKS00028829RSAPHARM Arzneimittel GmbH272
尚未招募
不适用
se of Hemopurifier Device For The Treatment of SARS-CoV-2 Virus Disease (COVID-19) in Humans.CTRI/2021/10/037591Aethlon Medical Inc